Regeneron制药公司看到投资者的兴趣增加,Q4的收益增加,增加了其股票。 Regeneron Pharmaceuticals saw increased investor interest and strong Q4 earnings, boosting its stock.

Regeneron制药公司第四季度的机构股份增加了3.8%,各投资者调整了股份。 Regeneron Pharmaceuticals saw a 3.8% rise in institutional holdings in the fourth quarter, with various investors adjusting their stakes. 该公司每股12.07美元的Q4收入比预测高0.86美元,并宣布每季度每股0.88美元的红利。 The company's Q4 earnings per share of $12.07 topped forecasts by $0.86, and it announced a quarterly dividend of $0.88 per share. 分析家对Regeneron的评级不尽相同,共识为“机动购买”,目标价格为973.13美元。 Analysts' ratings on Regeneron vary, with a consensus "Moderate Buy" and a target price of $973.13. 该公司的市场上限为790.9亿美元。 The company's market cap is $79.09 billion.